[E-Daily Reporter Shin Ha-yeon ] JETEMA Co.,Ltd.(216080)announced on the 6th that it is strengthening its cosmetics business by appointing Yoo Geun-jik, former CEO of Manyo Factory Co., Ltd., as Executive Vice President in charge of the derma-cosmetics division.

Executive Vice President Yoo is a professional manager who has led the growth of major domestic cosmetics brands for over 20 years. After graduating from Hanyang University with a degree in Business Administration, he served as an executive at Skinfood and The Face Shop before serving as CEO of It’s Skin and Manyo Factory Co., Ltd.

In particular, he gained experience in driving brand growth and enhancing corporate value by successfully leading the listing of It’s Skin on the KOSPI and Manyo Factory Co., Ltd. on KOSDAQ.

Through this appointment, JETEMA Co.,Ltd. plans to cultivate its derma-cosmetics business as a core growth driver by combining the research and development (R&D) capabilities it has accumulated in the medical aesthetics field with sales and marketing expertise in the cosmetics sector.

Executive Vice President Yoo will oversee the entire derma-cosmetics business, from product planning to the expansion of domestic and international distribution networks and global brand strategy. CEO Nam Jeong-seon plans to strengthen the professional management system by focusing on the company’s business strategy, medical aesthetics, and the development of new biopharmaceuticals.

JETEMA Co.,Ltd. plans to accelerate its entry into the global market for its derma-cosmetics business while expanding its new biopharmaceutical pipeline, which includes GLP-1-based obesity treatments and products for presbyopia correction. Through this, the company aims to build a “well-aging” portfolio that encompasses both medical aesthetics and the cosmetics business.

JETEMA Co.,Ltd. official stated, “Recruiting a professional manager who has successfully led two initial public offerings (IPOs) in the capital market demonstrates our commitment to growing the derma-cosmetics business to a global level,” adding, “We will leap forward to become a global total bio-healthcare company through synergies between our cosmetics business, which possesses stable cash generation capabilities, and the development of innovative new drugs.”